Key Takeaways
- GE Aerospace (GE) surged after beating Q2 estimates and raising its full-year free cash flow guidance to a range of $8.9B to $9.2B.
- Merck (MRK) received landmark FDA approval for Lipfendra, the first-of-its-kind daily pill designed to lower LDL cholesterol by up to 60%.
- Eli Lilly (LLY) announced a $2.8 billion upfront acquisition of AtaiBeckley (ATAI) to bolster its pipeline for treatment-resistant depression.
- Nvidia (NVDA) CEO Jensen Huang dismissed production delay rumors, stating the next-generation Vera Rubin AI systems are already in "giant" production.
- US Bancorp (USB) posted solid Q2 results with $7.71 billion in revenue, exceeding analyst expectations as regional banking stability continues.
Aerospace and Defense: GE Lifts Outlook on Services Strength
GE Aerospace (GE) delivered a robust second-quarter performance, reporting adjusted EPS of $2.02, which comfortably beat the consensus estimate of $1.86. The company’s adjusted revenue reached $12.63 billion, a 24% year-over-year increase fueled by a 27% surge in its Commercial Engines & Services segment.
Management significantly upgraded its fiscal 2026 outlook, now projecting operating profit between $10.55 billion and $10.75 billion. The most notable revision came in free cash flow, with the floor raised from $8.0 billion to $8.9 billion, reflecting high demand for shop visits and engine deliveries.
Healthcare: Merck’s Regulatory Win and Lilly’s Psychedelic Bet
The pharmaceutical sector saw two major developments this morning. Merck (MRK) secured FDA approval for Lipfendra, a daily PCSK9 inhibitor pill. This "super statin" alternative is expected to transform cardiovascular care by offering a more convenient, oral version of treatments that previously required injections, with a list price set at $10.50 per pill.
Simultaneously, Eli Lilly (LLY) moved to dominate the mental health space by acquiring AtaiBeckley (ATAI). The deal includes an upfront cash payment of $6.75 per share plus $2.50 in Contingent Value Rights (CVR), totaling a potential $3.8 billion. The acquisition centers on BPL-003, a rapid-acting intranasal compound for depression that aims to deliver results in days rather than weeks.
Technology and AI: Nvidia and Corning Gain Momentum
Nvidia (NVDA) CEO Jensen Huang provided a critical update from Tokyo, refuting reports of manufacturing bottlenecks for the company's next-generation AI hardware. Huang confirmed that Vera Rubin systems are currently in production, asserting that the industry is only "at the beginning of the cycle" for AI infrastructure expansion.
Supporting the AI build-out, Corning (GLW) received a price target hike from JPMorgan, moving from $185 to $200. Analysts cited Corning's pivotal role in wiring U.S. data centers, highlighted by recent multi-billion dollar supply agreements with Amazon, Meta, and Nvidia.
Financials and Commodities: Regional Banking Resilience
US Bancorp (USB) reported Q2 net income of $2.177 billion on revenue of $7.712 billion, beating the $7.583 billion estimate. The bank maintained a strong CET1 capital ratio of 10.8%, signaling balance sheet strength despite a broader market debate over the sustainability of 2026 earnings growth rates.
In commodities, UBS Global Wealth Management adjusted its stance on the global agriculture sector, downgrading it to Neutral from Moderately Overweight. Meanwhile, the Iraqi Oil Ministry confirmed that crude loading at southern terminals remains ongoing, providing some stability to energy markets amid regional tensions.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.